Skip to Content

Recent News, Awards and Honors

A study led by Michael Schwartz, MD, and published this week in Nature, showed that obese and diabetic mice that got a single shot of a growth-promoting peptide directly into their brains experienced lasting remission from the metabolic disorder without any sustained changes to their diet or their weight.
Steven Kahn, MB, ChB, will receive the Outstanding Achievement in Clinical Diabetes Research Award from the American Diabetes Association. This award recognizes exceptional contributions in patient-oriented, clinical outcomes research that have had a significant impact on diabetes prevention and treatment.
Michael Schwartz, MD, has received a $3.1 million grant from Novo Nordisk to collaborate on exploring the role of the brain in regulating blood glucose and obesity. The research will be conducted over the next three years, at South Lake Union research campus in Seattle, and at Novo Nordisk’s research facilities in Måløv, Denmark.
Karin Bornfeldt, PhD, has been awarded a new R01 from the NIH/NHLBI for her project: “Obesity and Arterial Metabolism.” The overall hypothesis is that expression of the glucose transporter GLUT1 is of critical importance for the obesity-induced arterial metabolic signature, smooth muscle cell phenotype, and obesity-accelerated atherosclerosis.

Basic Research

Basic research at the Center focuses on the multiple aspects underlying the pathogenesis of obesity and diabetes. The regulation of body weight involves hormones, such as ghrelin, leptin and insulin that act upon neurocircuits in the hypothalamus and other brain areas. Our studies have helped to develop and test the hypothesis that defects in the central nervous system (CNS) may unbalance the homeostasis of both energy balance and glucose metabolism and thus favor the progression of obesity, insulin resistance and type 2 diabetes. Clinical consequences of both type 1 and type 2 diabetes and their link to cardiovascular disease are also being investigated, with special emphasis on how these diseases affect the metabolism of cholesterol and lipoproteins, and how they disrupt cellular functions of macrophages and endothelial cells. The Center also aims to understand how the insulin-secreting pancreatic beta cell works and how its function is impaired in diabetes, and to identify autoimmune markers and mediators of type 1 diabetes.

Translational Research

The cure of any disease depends on a fundamental understanding of its causes. Only by identifying the elements involved in the initiation and progression of a disease can a cure be found.  An excellent example is cell-based therapy to treat diabetes. The goal is the implantation of insulin-producing cells to permit insulin delivery for type 1 diabetes patients without the need of immunosuppression. The successful implementation of this therapeutic approach requires application of a truly multidisciplinary approach involving stem cell biology, developmental, cellular and molecular biology of the pancreatic beta cell, immunology, and transplantation biology. We are building this comprehensive expertise at the Diabetes and Obesity Center of Excellence. Other areas of translational focus include study into the mechanisms whereby bariatric surgical procedures ameliorate diabetes, development of diagnostic testing to predict future development of type 1 diabetes, and the use of proteomic analysis of lipoproteins to gauge risk of heart attack.

Research Centers